Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
This is a somewhat nostalgic retro blog. I was leafing through a book by Vince Andriole called ‘The Quinolones’.[1] First released in 1988, its third edition is from 2000. It provided in-depth coverage of quinolone chemistry, PK, microbiology, efficacy and safety. It was a great review of the large and Continue reading ANTIBIOTIC DEVELOPMENT IN PHARMA IS DEAD – FOR NOW
At first glance, the list of features that distinguish AZD-0914 from other FQ seems impressive: broad Gram-positive and Gram-negative activity, MRSA and MSSA activity, potency against fluoroquinolone (FQ)-resistant isolates, low frequency for S. aureus resistance, and impressive activity against C. difficile. In addition, researchers mention a peculiar MoA for this gyrase/topoisomerase Continue reading AZD-0914: A New Broad-Spectrum Narrow-Development Path Drug
For GC antibiotics, the development path looks like a trip down the road less traveled, leading into some uncharted territory. Let’s take Melinta’s statement [1] at face value according to which the single 900 mg dose of delafloxacin failed because of “insufficient efficacy”. So, what then determines efficacy? Delafloxacin’s MIC90 was Continue reading Treating GC in the Face of Dwindling Antibiotic Options – (2)